BeiGene, Ltd.

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, VRTX has a market cap of 118.7B. Regarding current trading prices, BGNE is priced at $184.71, while VRTX trades at $462.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas VRTX's P/E ratio is -121.61. In terms of profitability, BGNE's ROE is -0.12%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, BGNE is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check VRTX's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, REGN has a market cap of 59.3B. Regarding current trading prices, BGNE is priced at $184.71, while REGN trades at $558.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas REGN's P/E ratio is 14.21. In terms of profitability, BGNE's ROE is -0.12%, compared to REGN's ROE of +0.14%. Regarding short-term risk, BGNE is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check REGN's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, ALNY has a market cap of 52.4B. Regarding current trading prices, BGNE is priced at $184.71, while ALNY trades at $401.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas ALNY's P/E ratio is -162.67. In terms of profitability, BGNE's ROE is -0.12%, compared to ALNY's ROE of -2.74%. Regarding short-term risk, BGNE is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check ALNY's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, BGNE is priced at $184.71, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas SGEN's P/E ratio is -57.19. In terms of profitability, BGNE's ROE is -0.12%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, BGNE is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check SGEN's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, ARGX has a market cap of 41.2B. Regarding current trading prices, BGNE is priced at $184.71, while ARGX trades at $673.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas ARGX's P/E ratio is 41.06. In terms of profitability, BGNE's ROE is -0.12%, compared to ARGX's ROE of +0.23%. Regarding short-term risk, BGNE is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check ARGX's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, BNTX has a market cap of 25.8B. Regarding current trading prices, BGNE is priced at $184.71, while BNTX trades at $107.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas BNTX's P/E ratio is -29.01. In terms of profitability, BGNE's ROE is -0.12%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, BGNE is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check BNTX's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, RPRX has a market cap of 20.9B. Regarding current trading prices, BGNE is priced at $184.71, while RPRX trades at $37.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas RPRX's P/E ratio is 15.15. In terms of profitability, BGNE's ROE is -0.12%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, BGNE is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check RPRX's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, SMMT has a market cap of 20.1B. Regarding current trading prices, BGNE is priced at $184.71, while SMMT trades at $27.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas SMMT's P/E ratio is -79.62. In terms of profitability, BGNE's ROE is -0.12%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, BGNE is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check SMMT's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, BGNE is priced at $184.71, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, BGNE's ROE is -0.12%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, BGNE is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check DNA-WT's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, INCY has a market cap of 14.8B. Regarding current trading prices, BGNE is priced at $184.71, while INCY trades at $75.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas INCY's P/E ratio is 17.87. In terms of profitability, BGNE's ROE is -0.12%, compared to INCY's ROE of +0.34%. Regarding short-term risk, BGNE is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check INCY's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, GMAB has a market cap of 13.7B. Regarding current trading prices, BGNE is priced at $184.71, while GMAB trades at $21.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas GMAB's P/E ratio is 12.81. In terms of profitability, BGNE's ROE is -0.12%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, BGNE is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check GMAB's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, UTHR has a market cap of 13.3B. Regarding current trading prices, BGNE is priced at $184.71, while UTHR trades at $294.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas UTHR's P/E ratio is 11.48. In terms of profitability, BGNE's ROE is -0.12%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, BGNE is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check UTHR's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, BGNE is priced at $184.71, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas KRTX's P/E ratio is -28.09. In terms of profitability, BGNE's ROE is -0.12%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, BGNE is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check KRTX's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, BMRN has a market cap of 11.1B. Regarding current trading prices, BGNE is priced at $184.71, while BMRN trades at $58.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas BMRN's P/E ratio is 21.53. In terms of profitability, BGNE's ROE is -0.12%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, BGNE is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check BMRN's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, MRNA has a market cap of 10.7B. Regarding current trading prices, BGNE is priced at $184.71, while MRNA trades at $27.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas MRNA's P/E ratio is -3.16. In terms of profitability, BGNE's ROE is -0.12%, compared to MRNA's ROE of -0.27%. Regarding short-term risk, BGNE is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check MRNA's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, ASND has a market cap of 10.5B. Regarding current trading prices, BGNE is priced at $184.71, while ASND trades at $174.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas ASND's P/E ratio is -25.89. In terms of profitability, BGNE's ROE is -0.12%, compared to ASND's ROE of +1.91%. Regarding short-term risk, BGNE is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check ASND's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, EXEL has a market cap of 10B. Regarding current trading prices, BGNE is priced at $184.71, while EXEL trades at $37.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas EXEL's P/E ratio is 17.91. In terms of profitability, BGNE's ROE is -0.12%, compared to EXEL's ROE of +0.28%. Regarding short-term risk, BGNE is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check EXEL's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, BGNE is priced at $184.71, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas RXDX's P/E ratio is -56.47. In terms of profitability, BGNE's ROE is -0.12%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, BGNE is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check RXDX's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, BBIO has a market cap of 9B. Regarding current trading prices, BGNE is priced at $184.71, while BBIO trades at $47.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas BBIO's P/E ratio is -13.31. In terms of profitability, BGNE's ROE is -0.12%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, BGNE is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check BBIO's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, VRNA has a market cap of 8.9B. Regarding current trading prices, BGNE is priced at $184.71, while VRNA trades at $105.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas VRNA's P/E ratio is -52.59. In terms of profitability, BGNE's ROE is -0.12%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, BGNE is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check VRNA's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, BGNE is priced at $184.71, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas IMGN's P/E ratio is -111.55. In terms of profitability, BGNE's ROE is -0.12%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, BGNE is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check IMGN's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, TECH has a market cap of 8.6B. Regarding current trading prices, BGNE is priced at $184.71, while TECH trades at $54.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas TECH's P/E ratio is 66.13. In terms of profitability, BGNE's ROE is -0.12%, compared to TECH's ROE of +0.06%. Regarding short-term risk, BGNE is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check TECH's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, BGNE is priced at $184.71, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas BPMC's P/E ratio is -51.58. In terms of profitability, BGNE's ROE is -0.12%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, BGNE is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check BPMC's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, BGNE is priced at $184.71, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas CERE's P/E ratio is -16.47. In terms of profitability, BGNE's ROE is -0.12%, compared to CERE's ROE of -0.43%. Regarding short-term risk, BGNE is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check CERE's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, BGNE is priced at $184.71, while ROIVW trades at $2.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, BGNE's ROE is -0.12%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, BGNE is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check ROIVW's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, ROIV has a market cap of 7.7B. Regarding current trading prices, BGNE is priced at $184.71, while ROIV trades at $11.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas ROIV's P/E ratio is -15.09. In terms of profitability, BGNE's ROE is -0.12%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, BGNE is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check ROIV's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, CORT has a market cap of 7.3B. Regarding current trading prices, BGNE is priced at $184.71, while CORT trades at $69.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas CORT's P/E ratio is 60.00. In terms of profitability, BGNE's ROE is -0.12%, compared to CORT's ROE of +0.20%. Regarding short-term risk, BGNE is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check CORT's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, HALO has a market cap of 7.3B. Regarding current trading prices, BGNE is priced at $184.71, while HALO trades at $59.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas HALO's P/E ratio is 15.70. In terms of profitability, BGNE's ROE is -0.12%, compared to HALO's ROE of +1.22%. Regarding short-term risk, BGNE is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check HALO's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, JAZZ has a market cap of 7B. Regarding current trading prices, BGNE is priced at $184.71, while JAZZ trades at $115.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas JAZZ's P/E ratio is 15.70. In terms of profitability, BGNE's ROE is -0.12%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, BGNE is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check JAZZ's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, IONS has a market cap of 6.9B. Regarding current trading prices, BGNE is priced at $184.71, while IONS trades at $43.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas IONS's P/E ratio is -24.45. In terms of profitability, BGNE's ROE is -0.12%, compared to IONS's ROE of -0.45%. Regarding short-term risk, BGNE is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check IONS's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, RVMD has a market cap of 6.8B. Regarding current trading prices, BGNE is priced at $184.71, while RVMD trades at $36.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas RVMD's P/E ratio is -9.13. In terms of profitability, BGNE's ROE is -0.12%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, BGNE is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check RVMD's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, MDGL has a market cap of 6.7B. Regarding current trading prices, BGNE is priced at $184.71, while MDGL trades at $302.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas MDGL's P/E ratio is -16.95. In terms of profitability, BGNE's ROE is -0.12%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, BGNE is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check MDGL's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, BGNE is priced at $184.71, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas RETA's P/E ratio is -66.29. In terms of profitability, BGNE's ROE is -0.12%, compared to RETA's ROE of +0.47%. Regarding short-term risk, BGNE is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check RETA's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, RYTM has a market cap of 5.8B. Regarding current trading prices, BGNE is priced at $184.71, while RYTM trades at $88.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas RYTM's P/E ratio is -31.54. In terms of profitability, BGNE's ROE is -0.12%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, BGNE is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check RYTM's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, NUVL has a market cap of 5.6B. Regarding current trading prices, BGNE is priced at $184.71, while NUVL trades at $77.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas NUVL's P/E ratio is -17.59. In terms of profitability, BGNE's ROE is -0.12%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, BGNE is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check NUVL's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, TGTX has a market cap of 5.6B. Regarding current trading prices, BGNE is priced at $184.71, while TGTX trades at $35.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas TGTX's P/E ratio is 140.08. In terms of profitability, BGNE's ROE is -0.12%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, BGNE is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check TGTX's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, BGNE is priced at $184.71, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, BGNE's ROE is -0.12%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, BGNE is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check ABCM's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, BGNE is priced at $184.71, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas ISEE's P/E ratio is -22.44. In terms of profitability, BGNE's ROE is -0.12%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, BGNE is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check ISEE's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, ABVX has a market cap of 5.4B. Regarding current trading prices, BGNE is priced at $184.71, while ABVX trades at $71.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas ABVX's P/E ratio is -21.10. In terms of profitability, BGNE's ROE is -0.12%, compared to ABVX's ROE of -1.06%. Regarding short-term risk, BGNE is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check ABVX's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, AXSM has a market cap of 5.1B. Regarding current trading prices, BGNE is priced at $184.71, while AXSM trades at $103.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas AXSM's P/E ratio is -17.85. In terms of profitability, BGNE's ROE is -0.12%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, BGNE is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check AXSM's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, MRUS has a market cap of 4.9B. Regarding current trading prices, BGNE is priced at $184.71, while MRUS trades at $65.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas MRUS's P/E ratio is -15.76. In terms of profitability, BGNE's ROE is -0.12%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, BGNE is less volatile compared to MRUS. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check MRUS's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, CRSP has a market cap of 4.8B. Regarding current trading prices, BGNE is priced at $184.71, while CRSP trades at $56.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas CRSP's P/E ratio is -12.49. In terms of profitability, BGNE's ROE is -0.12%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, BGNE is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check CRSP's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, ADMA has a market cap of 4.6B. Regarding current trading prices, BGNE is priced at $184.71, while ADMA trades at $19.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas ADMA's P/E ratio is 23.01. In terms of profitability, BGNE's ROE is -0.12%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, BGNE is less volatile compared to ADMA. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check ADMA's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, KRYS has a market cap of 4.5B. Regarding current trading prices, BGNE is priced at $184.71, while KRYS trades at $156.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas KRYS's P/E ratio is 37.65. In terms of profitability, BGNE's ROE is -0.12%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, BGNE is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check KRYS's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, SLNO has a market cap of 4.5B. Regarding current trading prices, BGNE is priced at $184.71, while SLNO trades at $86.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas SLNO's P/E ratio is -18.14. In terms of profitability, BGNE's ROE is -0.12%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, BGNE is less volatile compared to SLNO. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check SLNO's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, BGNE is priced at $184.71, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas ALPN's P/E ratio is -101.52. In terms of profitability, BGNE's ROE is -0.12%, compared to ALPN's ROE of -0.04%. Regarding short-term risk, BGNE is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check ALPN's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, TLX has a market cap of 4.4B. Regarding current trading prices, BGNE is priced at $184.71, while TLX trades at $13.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas TLX's P/E ratio is 145.00. In terms of profitability, BGNE's ROE is -0.12%, compared to TLX's ROE of +0.06%. Regarding short-term risk, BGNE is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check TLX's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, ALKS has a market cap of 4.4B. Regarding current trading prices, BGNE is priced at $184.71, while ALKS trades at $26.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas ALKS's P/E ratio is 12.83. In terms of profitability, BGNE's ROE is -0.12%, compared to ALKS's ROE of +0.24%. Regarding short-term risk, BGNE is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check ALKS's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, CYTK has a market cap of 4.4B. Regarding current trading prices, BGNE is priced at $184.71, while CYTK trades at $36.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas CYTK's P/E ratio is -6.94. In terms of profitability, BGNE's ROE is -0.12%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, BGNE is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check CYTK's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, RNA has a market cap of 4.3B. Regarding current trading prices, BGNE is priced at $184.71, while RNA trades at $35.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas RNA's P/E ratio is -11.97. In terms of profitability, BGNE's ROE is -0.12%, compared to RNA's ROE of -0.27%. Regarding short-term risk, BGNE is less volatile compared to RNA. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check RNA's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, PCVX has a market cap of 4.3B. Regarding current trading prices, BGNE is priced at $184.71, while PCVX trades at $33.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas PCVX's P/E ratio is -8.28. In terms of profitability, BGNE's ROE is -0.12%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, BGNE is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check PCVX's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, BGNE is priced at $184.71, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas OPT's P/E ratio is -1.52. In terms of profitability, BGNE's ROE is -0.12%, compared to OPT's ROE of +2.60%. Regarding short-term risk, BGNE is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check OPT's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, PTCT has a market cap of 4.1B. Regarding current trading prices, BGNE is priced at $184.71, while PTCT trades at $52.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas PTCT's P/E ratio is 8.01. In terms of profitability, BGNE's ROE is -0.12%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, BGNE is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check PTCT's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, BGNE is priced at $184.71, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas MRTX's P/E ratio is -4.82. In terms of profitability, BGNE's ROE is -0.12%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, BGNE is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check MRTX's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, ZLAB has a market cap of 4.1B. Regarding current trading prices, BGNE is priced at $184.71, while ZLAB trades at $36.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas ZLAB's P/E ratio is -14.73. In terms of profitability, BGNE's ROE is -0.12%, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, BGNE is less volatile compared to ZLAB. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check ZLAB's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, ACAD has a market cap of 3.9B. Regarding current trading prices, BGNE is priced at $184.71, while ACAD trades at $23.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas ACAD's P/E ratio is 17.18. In terms of profitability, BGNE's ROE is -0.12%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, BGNE is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check ACAD's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, ACLX has a market cap of 3.9B. Regarding current trading prices, BGNE is priced at $184.71, while ACLX trades at $71.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas ACLX's P/E ratio is -23.79. In terms of profitability, BGNE's ROE is -0.12%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, BGNE is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check ACLX's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, AKRO has a market cap of 3.9B. Regarding current trading prices, BGNE is priced at $184.71, while AKRO trades at $48.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas AKRO's P/E ratio is -12.90. In terms of profitability, BGNE's ROE is -0.12%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, BGNE is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check AKRO's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, BGNE is priced at $184.71, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas RYZB's P/E ratio is -57.86. In terms of profitability, BGNE's ROE is -0.12%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, BGNE is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check RYZB's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, BGNE is priced at $184.71, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas CBAY's P/E ratio is -32.81. In terms of profitability, BGNE's ROE is -0.12%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, BGNE is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check CBAY's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, BGNE is priced at $184.71, while VKTX trades at $32.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas VKTX's P/E ratio is -21.22. In terms of profitability, BGNE's ROE is -0.12%, compared to VKTX's ROE of -0.20%. Regarding short-term risk, BGNE is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check VKTX's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, MTSR has a market cap of 3.7B. Regarding current trading prices, BGNE is priced at $184.71, while MTSR trades at $34.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas MTSR's P/E ratio is -11.91. In terms of profitability, BGNE's ROE is -0.12%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, BGNE is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check MTSR's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, LEGN has a market cap of 3.6B. Regarding current trading prices, BGNE is priced at $184.71, while LEGN trades at $38.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas LEGN's P/E ratio is -32.88. In terms of profitability, BGNE's ROE is -0.12%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, BGNE is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check LEGN's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, BGNE is priced at $184.71, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas SWTX's P/E ratio is -13.78. In terms of profitability, BGNE's ROE is -0.12%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, BGNE is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check SWTX's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, SRRK has a market cap of 3.5B. Regarding current trading prices, BGNE is priced at $184.71, while SRRK trades at $36.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas SRRK's P/E ratio is -14.26. In terms of profitability, BGNE's ROE is -0.12%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, BGNE is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check SRRK's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, AAPG has a market cap of 3.4B. Regarding current trading prices, BGNE is priced at $184.71, while AAPG trades at $37.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas AAPG's P/E ratio is -49.07. In terms of profitability, BGNE's ROE is -0.12%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, BGNE is less volatile compared to AAPG. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check AAPG's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, MLTX has a market cap of 3.3B. Regarding current trading prices, BGNE is priced at $184.71, while MLTX trades at $52.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas MLTX's P/E ratio is -22.94. In terms of profitability, BGNE's ROE is -0.12%, compared to MLTX's ROE of -0.31%. Regarding short-term risk, BGNE is less volatile compared to MLTX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check MLTX's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, PTGX has a market cap of 3.3B. Regarding current trading prices, BGNE is priced at $184.71, while PTGX trades at $53.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas PTGX's P/E ratio is 69.01. In terms of profitability, BGNE's ROE is -0.12%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, BGNE is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check PTGX's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, KYMR has a market cap of 3B. Regarding current trading prices, BGNE is priced at $184.71, while KYMR trades at $42.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas KYMR's P/E ratio is -13.81. In terms of profitability, BGNE's ROE is -0.12%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, BGNE is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check KYMR's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, APLS has a market cap of 2.9B. Regarding current trading prices, BGNE is priced at $184.71, while APLS trades at $22.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas APLS's P/E ratio is -12.54. In terms of profitability, BGNE's ROE is -0.12%, compared to APLS's ROE of -1.16%. Regarding short-term risk, BGNE is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check APLS's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, BGNE is priced at $184.71, while MORF trades at $56.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas MORF's P/E ratio is -14.88. In terms of profitability, BGNE's ROE is -0.12%, compared to MORF's ROE of -0.22%. Regarding short-term risk, BGNE is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check MORF's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, BGNE is priced at $184.71, while MOR trades at $18.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas MOR's P/E ratio is -12.64. In terms of profitability, BGNE's ROE is -0.12%, compared to MOR's ROE of -1.84%. Regarding short-term risk, BGNE is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check MOR's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, BGNE is priced at $184.71, while KDNY trades at $40.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas KDNY's P/E ratio is -12.47. In terms of profitability, BGNE's ROE is -0.12%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, BGNE is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check KDNY's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, RARE has a market cap of 2.7B. Regarding current trading prices, BGNE is priced at $184.71, while RARE trades at $28.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas RARE's P/E ratio is -4.88. In terms of profitability, BGNE's ROE is -0.12%, compared to RARE's ROE of -1.86%. Regarding short-term risk, BGNE is less volatile compared to RARE. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check RARE's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, IMVT has a market cap of 2.7B. Regarding current trading prices, BGNE is priced at $184.71, while IMVT trades at $15.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas IMVT's P/E ratio is -5.75. In terms of profitability, BGNE's ROE is -0.12%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, BGNE is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check IMVT's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, BGNE is priced at $184.71, while MYOV trades at $26.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas MYOV's P/E ratio is -14.05. In terms of profitability, BGNE's ROE is -0.12%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, BGNE is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check MYOV's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, CRNX has a market cap of 2.6B. Regarding current trading prices, BGNE is priced at $184.71, while CRNX trades at $27.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas CRNX's P/E ratio is -7.33. In terms of profitability, BGNE's ROE is -0.12%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, BGNE is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check CRNX's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, MIRM has a market cap of 2.6B. Regarding current trading prices, BGNE is priced at $184.71, while MIRM trades at $52.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas MIRM's P/E ratio is -32.31. In terms of profitability, BGNE's ROE is -0.12%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, BGNE is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check MIRM's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, CPRX has a market cap of 2.6B. Regarding current trading prices, BGNE is priced at $184.71, while CPRX trades at $21.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas CPRX's P/E ratio is 13.45. In terms of profitability, BGNE's ROE is -0.12%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, BGNE is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check CPRX's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, LGND has a market cap of 2.6B. Regarding current trading prices, BGNE is priced at $184.71, while LGND trades at $132.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas LGND's P/E ratio is -18.21. In terms of profitability, BGNE's ROE is -0.12%, compared to LGND's ROE of -0.16%. Regarding short-term risk, BGNE is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check LGND's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, RXRX has a market cap of 2.4B. Regarding current trading prices, BGNE is priced at $184.71, while RXRX trades at $5.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas RXRX's P/E ratio is -3.16. In terms of profitability, BGNE's ROE is -0.12%, compared to RXRX's ROE of -0.75%. Regarding short-term risk, BGNE is less volatile compared to RXRX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check RXRX's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, NAMS has a market cap of 2.4B. Regarding current trading prices, BGNE is priced at $184.71, while NAMS trades at $21.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas NAMS's P/E ratio is -11.57. In terms of profitability, BGNE's ROE is -0.12%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, BGNE is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check NAMS's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, BGNE is priced at $184.71, while PRVB trades at $24.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas PRVB's P/E ratio is -16.43. In terms of profitability, BGNE's ROE is -0.12%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, BGNE is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check PRVB's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, KNSA has a market cap of 2.4B. Regarding current trading prices, BGNE is priced at $184.71, while KNSA trades at $31.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas KNSA's P/E ratio is 639.60. In terms of profitability, BGNE's ROE is -0.12%, compared to KNSA's ROE of +0.01%. Regarding short-term risk, BGNE is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check KNSA's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, BGNE is priced at $184.71, while LBPH trades at $59.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas LBPH's P/E ratio is -26.66. In terms of profitability, BGNE's ROE is -0.12%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, BGNE is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check LBPH's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, XENE has a market cap of 2.3B. Regarding current trading prices, BGNE is priced at $184.71, while XENE trades at $30.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas XENE's P/E ratio is -9.47. In terms of profitability, BGNE's ROE is -0.12%, compared to XENE's ROE of -0.32%. Regarding short-term risk, BGNE is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check XENE's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, NAMSW has a market cap of 2.3B. Regarding current trading prices, BGNE is priced at $184.71, while NAMSW trades at $10.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas NAMSW's P/E ratio is N/A. In terms of profitability, BGNE's ROE is -0.12%, compared to NAMSW's ROE of -0.33%. Regarding short-term risk, BGNE is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check NAMSW's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, BGNE is priced at $184.71, while DICE trades at $47.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas DICE's P/E ratio is -21.91. In terms of profitability, BGNE's ROE is -0.12%, compared to DICE's ROE of +0.56%. Regarding short-term risk, BGNE is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for BGNE.Check DICE's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, APGE has a market cap of 2.2B. Regarding current trading prices, BGNE is priced at $184.71, while APGE trades at $37.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas APGE's P/E ratio is -10.46. In terms of profitability, BGNE's ROE is -0.12%, compared to APGE's ROE of -0.19%. Regarding short-term risk, BGNE is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check APGE's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, CNTA has a market cap of 2.2B. Regarding current trading prices, BGNE is priced at $184.71, while CNTA trades at $16.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas CNTA's P/E ratio is -8.94. In terms of profitability, BGNE's ROE is -0.12%, compared to CNTA's ROE of -0.57%. Regarding short-term risk, BGNE is less volatile compared to CNTA. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check CNTA's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, ARWR has a market cap of 2.2B. Regarding current trading prices, BGNE is priced at $184.71, while ARWR trades at $15.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas ARWR's P/E ratio is -12.85. In terms of profitability, BGNE's ROE is -0.12%, compared to ARWR's ROE of -0.46%. Regarding short-term risk, BGNE is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check ARWR's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, IBRX has a market cap of 2.2B. Regarding current trading prices, BGNE is priced at $184.71, while IBRX trades at $2.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas IBRX's P/E ratio is -4.16. In terms of profitability, BGNE's ROE is -0.12%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, BGNE is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check IBRX's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, GLPG has a market cap of 2.2B. Regarding current trading prices, BGNE is priced at $184.71, while GLPG trades at $32.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas GLPG's P/E ratio is -6.44. In terms of profitability, BGNE's ROE is -0.12%, compared to GLPG's ROE of -0.10%. Regarding short-term risk, BGNE is less volatile compared to GLPG. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check GLPG's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, BGNE is priced at $184.71, while CALT trades at $40.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas CALT's P/E ratio is -22.73. In terms of profitability, BGNE's ROE is -0.12%, compared to CALT's ROE of -1.67%. Regarding short-term risk, BGNE is less volatile compared to CALT. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check CALT's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, BLTE has a market cap of 2.1B. Regarding current trading prices, BGNE is priced at $184.71, while BLTE trades at $65.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas BLTE's P/E ratio is -48.32. In terms of profitability, BGNE's ROE is -0.12%, compared to BLTE's ROE of -0.32%. Regarding short-term risk, BGNE is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check BLTE's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, IDYA has a market cap of 2.1B. Regarding current trading prices, BGNE is priced at $184.71, while IDYA trades at $24.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas IDYA's P/E ratio is -6.65. In terms of profitability, BGNE's ROE is -0.12%, compared to IDYA's ROE of -0.29%. Regarding short-term risk, BGNE is less volatile compared to IDYA. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check IDYA's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, IRON has a market cap of 2B. Regarding current trading prices, BGNE is priced at $184.71, while IRON trades at $58.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas IRON's P/E ratio is -15.16. In terms of profitability, BGNE's ROE is -0.12%, compared to IRON's ROE of -0.23%. Regarding short-term risk, BGNE is less volatile compared to IRON. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check IRON's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, AGIO has a market cap of 2B. Regarding current trading prices, BGNE is priced at $184.71, while AGIO trades at $35.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas AGIO's P/E ratio is 3.03. In terms of profitability, BGNE's ROE is -0.12%, compared to AGIO's ROE of +0.43%. Regarding short-term risk, BGNE is less volatile compared to AGIO. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check AGIO's competition here

BGNE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BGNE stands at 20.2B. In comparison, CGON has a market cap of 2B. Regarding current trading prices, BGNE is priced at $184.71, while CGON trades at $26.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BGNE currently has a P/E ratio of -22.55, whereas CGON's P/E ratio is -17.54. In terms of profitability, BGNE's ROE is -0.12%, compared to CGON's ROE of -0.17%. Regarding short-term risk, BGNE is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for BGNE.Check CGON's competition here